SRS4 Antibody

What is SRSF4 and why is it significant in molecular biology research?

SRSF4 (Serine/arginine-rich splicing factor 4) encodes the protein SRp75, which belongs to the arginine/serine-rich (SR) factor family. These proteins are critical in RNA metabolism, particularly in alternative mRNA splicing processes. SRSF4 contains RNA recognition motifs (RRM) and an arginine/serine (RS)-rich domain, which are characteristic of this protein family. The significance of SRSF4 lies in its essential role in both constitutive splicing and the regulation of alternative splicing in a concentration-dependent manner, making it a crucial target for studies investigating gene expression regulation mechanisms and RNA processing .

How do SRSF4 antibodies differ from other SR protein-targeting antibodies?

SRSF4 antibodies are specifically designed to recognize unique epitopes on the SRp75 protein that distinguish it from other SR family members. While all SR proteins share common structural features (RRM domains and RS-rich regions), SRSF4 antibodies target specific sequences or conformational epitopes unique to SRp75. This specificity is crucial because SR proteins have distinct subcellular localizations and functions – most SR proteins like SC35 and SRp40 are confined to the nucleus, while others like SF2/ASF, SRp20, and 9G8 shuttle between the nucleus and cytoplasm . When selecting an SRSF4 antibody, researchers should verify cross-reactivity testing against other SR family members to ensure specificity, especially when studying splicing regulation where multiple SR proteins may be present in the same complex.

What are the common alternative names for SRSF4 that should be recognized when searching for antibodies?

When searching for SRSF4 antibodies in scientific literature or commercial catalogs, researchers should be aware of numerous alternative designations:

Recognizing these alternative nomenclatures is essential for comprehensive literature searches and identifying appropriate antibodies for research applications .

What validation methods should be used to confirm SRSF4 antibody specificity?

Confirming SRSF4 antibody specificity requires multiple complementary validation approaches:

• Western blot analysis: Verify a single band at the expected molecular weight (approximately 75 kDa) in relevant cell/tissue lysates.

• Knockdown/knockout controls: Compare antibody signal in wild-type samples versus SRSF4-depleted samples (siRNA/shRNA knockdown or CRISPR knockout).

• Immunoprecipitation followed by mass spectrometry: Confirm that the antibody pulls down SRSF4 and expected binding partners, using techniques similar to those employed in antibody sequencing via LC-MS/MS .

• Peptide competition assay: Pre-incubate the antibody with a synthetic peptide corresponding to the immunogen to demonstrate signal ablation.

• Cross-reactivity testing: Evaluate potential cross-reactivity with other SR family proteins, particularly those with high sequence homology.

A properly validated SRSF4 antibody should demonstrate consistent results across multiple cell types and experimental conditions, with minimal background and high signal-to-noise ratio in the specific applications intended.

How should researchers select between monoclonal and polyclonal SRSF4 antibodies for different applications?

The selection between monoclonal and polyclonal SRSF4 antibodies depends on the specific research application:

What criteria should be used when designing custom SRSF4 antibodies for specialized research applications?

When designing custom SRSF4 antibodies for specialized applications, researchers should consider:

• Epitope selection: Choose regions unique to SRSF4 that avoid conserved domains shared with other SR proteins. The variable regions between RRM domains or unique sequences within the RS domain are often good targets.

• Immunogen design: For phosphorylation-specific antibodies, design peptides with phosphorylated residues at specific positions known to regulate SRSF4 activity.

• Species conservation: Consider sequence homology across species if cross-reactivity with orthologs is desired for comparative studies.

• Application compatibility: Design constructs compatible with the intended application (e.g., native conditions for IP, denatured for Western blotting).

• Validation strategy: Implement rigorous validation protocols similar to those used for antibody sequencing via LC-MS/MS to confirm specificity .

• Production and purification: Select appropriate expression systems and purification methods to ensure antibody functionality and stability.

Custom SRSF4 antibodies should undergo extensive validation in systems where SRSF4 is either overexpressed or depleted to confirm specificity before application in complex experimental settings.

What are the optimal conditions for using SRSF4 antibodies in chromatin immunoprecipitation (ChIP) experiments?

Optimizing SRSF4 antibodies for ChIP experiments requires attention to several critical parameters:

• Crosslinking conditions: Standard formaldehyde crosslinking (1% for 10 minutes) may be insufficient for capturing transient RNA-protein interactions. Consider dual crosslinking with disuccinimidyl glutarate (DSG) followed by formaldehyde to stabilize protein-protein interactions within splicing complexes.

• Sonication parameters: Aim for chromatin fragments of 200-500 bp, using optimization with different sonication times and amplitudes.

• Buffer composition: Include RNase inhibitors if investigating RNA-dependent chromatin associations. Consider using buffers with varying salt concentrations (150-300 mM NaCl) to optimize specificity.

• Antibody concentration: Typically 3-5 μg of antibody per IP reaction, though this should be titrated for each application.

• Controls: Always include:

  • IgG control to assess non-specific binding

  • Input samples (typically 5-10% of starting material)

  • Positive control (antibody against known chromatin-associated protein)

  • Spike-in controls for normalization across samples

• Washing conditions: Stringent washing conditions (including LiCl wash buffer) are essential to reduce background without disrupting specific interactions.

The success of SRSF4 ChIP experiments can be verified by qPCR analysis of known SRSF4-associated genomic regions before proceeding to genome-wide analyses like ChIP-seq.

How can SRSF4 antibodies be effectively used to study alternative splicing events in disease models?

To effectively study alternative splicing events using SRSF4 antibodies in disease models:

• RNA immunoprecipitation (RIP): Optimize RIP protocols to capture SRSF4-RNA interactions by:

  • Using crosslinking conditions that preserve RNA integrity

  • Including RNase inhibitors in all buffers

  • Validating enrichment of known SRSF4 RNA targets by RT-qPCR

• Immunofluorescence combined with RNA-FISH: To visualize co-localization of SRSF4 with specific transcripts:

  • Fix cells with paraformaldehyde (4%, 10 minutes)

  • Permeabilize with 0.5% Triton X-100

  • Block with 3% BSA

  • Incubate with SRSF4 antibody (typically 1:100-1:500 dilution)

  • Perform RNA-FISH for target transcripts

  • Analyze co-localization using confocal microscopy

• CLIP-seq applications: For genome-wide identification of SRSF4 binding sites:

  • Crosslink cells with UV irradiation (254 nm, 400 mJ/cm²)

  • Immunoprecipitate SRSF4-RNA complexes using validated antibodies

  • Process samples for high-throughput sequencing

  • Analyze binding motifs and correlation with alternative splicing events

• Splicing reporter assays: To functionally validate SRSF4 effects:

  • Design minigene constructs containing exons of interest

  • Manipulate SRSF4 levels (overexpression/knockdown)

  • Assess splicing patterns by RT-PCR

  • Correlate with SRSF4 binding (validated by RIP or CLIP)

These approaches can be particularly valuable in disease models where splicing dysregulation is implicated, such as certain cancers or neurological disorders where SR protein function may be altered.

What protocol modifications are necessary when using SRSF4 antibodies for co-immunoprecipitation of splicing complexes?

When using SRSF4 antibodies for co-immunoprecipitation (co-IP) of splicing complexes, several protocol modifications are necessary:

• Lysis conditions: Use gentle lysis buffers (e.g., 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, 1 mM EDTA) supplemented with:

  • Phosphatase inhibitors (critical as SR protein function is regulated by phosphorylation)

  • Protease inhibitors

  • RNase inhibitors (if RNA-dependent interactions are being studied)

• Nuclear extraction: Since SRSF4 is predominantly nuclear, optimize nuclear extraction protocols to ensure efficient recovery.

• Pre-clearing: Extensive pre-clearing with protein A/G beads (1-2 hours at 4°C) to reduce non-specific binding.

• Antibody binding conditions:

  • Pre-bind antibodies to protein A/G beads for 1-2 hours

  • Use 2-5 μg antibody per mg of protein lysate

  • Extend incubation times (overnight at 4°C) to capture transient interactions

• RNase treatment controls: Include parallel samples with RNase treatment to distinguish RNA-dependent from RNA-independent interactions.

• Washing stringency: Use progressively increasing salt concentrations (150-300 mM NaCl) in wash buffers to remove weakly associated proteins while maintaining specific interactions.

• Elution conditions: Consider native elution with competing peptides for downstream functional assays, or use standard SDS elution for mass spectrometry analysis.

For detection of SRSF4 interaction partners, mass spectrometry approaches similar to those used in antibody sequencing via LC-MS/MS can be adapted to identify components of splicing complexes .

How can researchers address non-specific binding issues when using SRSF4 antibodies in complex samples?

When encountering non-specific binding with SRSF4 antibodies in complex samples:

• Optimize blocking conditions:

  • Extend blocking time (1-2 hours)

  • Test alternative blocking agents (5% milk, 3-5% BSA, commercial blocking buffers)

  • Consider adding 0.1-0.5% Triton X-100 to reduce hydrophobic interactions

• Adjust antibody concentration and incubation conditions:

  • Perform antibody titration experiments (typically 1:500-1:5000 for Western blots)

  • Reduce incubation temperature (4°C instead of room temperature)

  • Extend incubation time with more dilute antibody concentration

• Modify washing protocols:

  • Increase number of washes (5-6 washes instead of standard 3)

  • Add detergents (0.1% SDS or 0.5% sodium deoxycholate) to washing buffers

  • Include salt washes (up to 500 mM NaCl) to disrupt low-affinity interactions

• Pre-absorb antibodies:

  • Incubate diluted antibody with lysate from cells lacking SRSF4 expression

  • Remove non-specific interactions by centrifugation before using in the actual experiment

• Validate with alternative detection methods:

  • Confirm findings using a second SRSF4 antibody targeting a different epitope

  • Use tagged SRSF4 constructs and tag-specific antibodies as complementary approach

• Consider sample complexity reduction:

  • Perform subcellular fractionation to enrich for nuclear proteins

  • Use phosphorylation-specific enrichment for SR proteins if appropriate

Implementing these strategies systematically can significantly improve the signal-to-noise ratio when working with SRSF4 antibodies in complex biological samples.

What are the best methods for quantitative analysis of SRSF4 expression across different cell types or disease states?

For quantitative analysis of SRSF4 expression across different samples:

• Western blot quantification:

  • Use validated loading controls appropriate for your sample type (β-actin for whole-cell lysates, histone H3 for nuclear fractions)

  • Implement linear range detection for both target and control

  • Utilize fluorescently-labeled secondary antibodies for more accurate quantification

  • Apply normalization to multiple housekeeping proteins for robust analysis

• Immunohistochemistry/Immunofluorescence quantification:

  • Use automated image analysis software with validated algorithms for nuclear protein quantification

  • Include standardization controls in each batch

  • Measure both intensity and subcellular distribution patterns

  • Apply tissue microarrays for high-throughput analysis across multiple samples

• Flow cytometry for SRSF4 detection:

  • Optimize fixation and permeabilization protocols for nuclear proteins

  • Include isotype controls and SRSF4-depleted controls

  • Use median fluorescence intensity for quantitative comparisons

  • Consider multiparameter analysis to correlate with cell cycle or differentiation markers

• RT-qPCR for mRNA expression:

  • Design primers spanning exon-exon junctions

  • Validate PCR efficiency using standard curves

  • Normalize to multiple reference genes selected for stability in your experimental system

  • Consider analyzing splicing isoforms in addition to total SRSF4 expression

• Mass spectrometry-based quantification:

  • Use stable isotope labeling approaches (SILAC, TMT, iTRAQ)

  • Include phosphorylation-specific enrichment to assess SRSF4 activation state

  • Monitor multiple peptides per protein for reliable quantification

  • Apply methods similar to those used in antibody research for accurate protein identification

Combining multiple quantitative approaches provides the most comprehensive assessment of SRSF4 expression and activation state across different experimental conditions.

How should researchers interpret conflicting results between different SRSF4 antibody-based detection methods?

When faced with conflicting results between different SRSF4 antibody-based detection methods:

• Evaluate epitope differences:

  • Map the epitopes recognized by each antibody

  • Consider whether post-translational modifications (especially phosphorylation) might affect epitope recognition

  • Assess whether protein conformation in different assays might mask specific epitopes

• Review method-specific limitations:

  • Western blot: Denatured proteins may expose epitopes not accessible in native conditions

  • IP: Buffer conditions might disrupt certain interactions or conformations

  • IHC/IF: Fixation methods can alter epitope accessibility

  • Flow cytometry: Permeabilization efficiency might affect nuclear protein detection

• Consider biological variables:

  • SRSF4 shuttling between nucleus and cytoplasm might affect detection

  • Alternative splicing of SRSF4 itself could generate isoforms recognized differently by various antibodies

  • Protein complexes might mask epitopes in co-IP but not in Western blots

• Implement orthogonal validation:

  • Use non-antibody methods (MS-based proteomics)

  • Apply genetic approaches (tagged SRSF4 constructs)

  • Perform functional assays to correlate with expression data

• Standardize experimental conditions:

  • Use consistent sample preparation across all detection methods

  • Apply the same controls to all approaches

  • Normalize data using the same reference standards

When reporting conflicting results, carefully document the specific antibodies used (including catalog numbers, lots, and dilutions) and detail the exact experimental conditions to enable proper interpretation and reproducibility.

How can SRSF4 antibodies be integrated into high-throughput screening approaches for splicing modulators?

Integrating SRSF4 antibodies into high-throughput screening for splicing modulators involves several strategic approaches:

• Automated immunofluorescence platforms:

  • Develop high-content screening assays monitoring SRSF4 nuclear speckle localization

  • Implement machine learning algorithms to quantify changes in SRSF4 distribution patterns

  • Use 384-well or 1536-well format with robotic liquid handling for compound libraries

  • Include phospho-specific SRSF4 antibodies to monitor activity-dependent changes

• FRET-based interaction screens:

  • Design assays with fluorescently-labeled SRSF4 antibody fragments and known binding partners

  • Monitor compound-induced changes in protein-protein interactions in real-time

  • Adapt for microplate reader format for primary screening

  • Validate hits with orthogonal binding assays

• AlphaScreen/AlphaLISA applications:

  • Develop homogeneous assays using SRSF4 antibodies coupled to donor beads

  • Pair with acceptor beads coupled to RNA substrates or protein partners

  • Optimize signal-to-background ratio for screening conditions

  • Implement counter-screens to eliminate false positives

• Splicing reporter systems:

  • Generate stable cell lines expressing splicing reporters sensitive to SRSF4 activity

  • Use SRSF4 antibodies to correlate compound effects with protein levels/modifications

  • Implement parallel readouts (luciferase activity and SRSF4 status)

  • Apply to primary patient samples for personalized medicine applications

• Automated Western blot systems:

  • Utilize capillary electrophoresis-based immunoassay platforms

  • Monitor changes in SRSF4 phosphorylation state across compound libraries

  • Establish quantitative thresholds for hit identification

  • Integrate with transcriptomic data on splicing changes

These approaches can be applied to screening compound libraries for molecules that modulate splicing in disease contexts where SRSF4 regulation is implicated.

What methodologies should be employed to study SRSF4 phosphorylation dynamics and their impact on splicing regulation?

To study SRSF4 phosphorylation dynamics and their impact on splicing:

• Phospho-specific antibody development:

  • Generate antibodies against key SRSF4 phosphorylation sites (primarily serine residues in the RS domain)

  • Validate specificity using phosphatase treatment and phospho-mimetic/phospho-dead mutants

  • Apply in multiple assay formats (Western blot, IP, IF) to track phosphorylation in different cellular compartments

• Mass spectrometry-based phosphoproteomics:

  • Employ TiO₂ or IMAC enrichment for phosphopeptides

  • Use parallel reaction monitoring (PRM) for targeted quantification of specific phosphosites

  • Apply kinase/phosphatase inhibitors to manipulate phosphorylation dynamics

  • Correlate phosphorylation patterns with splicing outcomes using techniques similar to antibody sequencing via LC-MS/MS

• In vitro splicing assays with phosphorylation modulation:

  • Purify SRSF4 using antibody-based affinity chromatography

  • Perform in vitro phosphorylation/dephosphorylation

  • Assess impact on splicing using minigene substrates

  • Correlate with structural changes using biophysical methods

• Live-cell imaging of phosphorylation dynamics:

  • Use FRET-based biosensors to monitor SRSF4 phosphorylation in real-time

  • Combine with fluorescently tagged splicing reporters

  • Apply optogenetic tools to induce phosphorylation with spatial/temporal precision

  • Correlate with SRSF4 localization and mobility using FRAP (Fluorescence Recovery After Photobleaching)

• Kinase-substrate relationship analysis:

  • Perform kinase inhibitor screens to identify regulators of SRSF4 phosphorylation

  • Validate with in vitro kinase assays using purified components

  • Develop phosphorylation-dependent interaction maps using BioID or proximity labeling

  • Create computational models of phosphorylation networks regulating SRSF4 function

These methodologies provide complementary approaches to understand how phosphorylation regulates SRSF4's role in splicing mechanics and can identify potential therapeutic targets in diseases with splicing dysregulation.

How can researchers integrate SRSF4 antibody data with transcriptomic and proteomic datasets for systems biology approaches?

Integrating SRSF4 antibody data with -omics datasets requires sophisticated computational and experimental strategies:

• Multi-omics data integration frameworks:

  • Collect matched samples for SRSF4 antibody-based assays, RNA-seq, and proteomics

  • Normalize datasets using appropriate technical and biological controls

  • Apply dimensionality reduction techniques (PCA, t-SNE, UMAP) to visualize relationships

  • Implement Bayesian network analysis to infer causal relationships between SRSF4 status and downstream effects

• SRSF4-centric splicing networks:

  • Perform CLIP-seq using validated SRSF4 antibodies to identify direct RNA targets

  • Correlate binding sites with alternative splicing events from RNA-seq

  • Validate key events using RT-PCR and minigene assays

  • Construct splicing regulatory networks centered on SRSF4

• Proteomic validation of splicing outcomes:

  • Use antibodies against SRSF4-regulated gene products to confirm alternative protein isoforms

  • Apply targeted proteomics to quantify isoform ratios at the protein level

  • Develop specific antibodies against splice junctions of interest

  • Correlate protein isoform abundance with SRSF4 levels/activity

• Perturbation-response profiling:

  • Apply SRSF4 knockdown/overexpression combined with transcriptomic and proteomic profiling

  • Use phosphorylation-specific antibodies to monitor signaling pathways affecting SRSF4

  • Implement CRISPR screens to identify genetic interactions with SRSF4

  • Develop predictive models of splicing outcomes based on SRSF4 status

• Translational applications:

  • Analyze patient samples using SRSF4 antibodies combined with transcriptomics

  • Correlate SRSF4 status with disease progression and treatment response

  • Develop biomarker panels incorporating SRSF4-regulated splicing events

  • Apply similar methodological approaches to those used in development of therapeutics targeting splicing mechanisms

Researchers should employ standardized protocols and consistent analytical pipelines across all datasets to ensure meaningful integration, utilizing specialized software packages designed for multi-omics data analysis.